These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33523340)

  • 1. Discovery and validation of an expression signature for recurrence prediction in high-risk diffuse-type gastric cancer.
    Lee IS; Sahu D; Hur H; Yook JH; Kim BS; Goel A
    Gastric Cancer; 2021 May; 24(3):655-665. PubMed ID: 33523340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomic Profiling Identifies a Risk Stratification Signature for Predicting Peritoneal Recurrence and Micrometastasis in Gastric Cancer.
    Lee IS; Lee H; Hur H; Kanda M; Yook JH; Kim BS; Woo Y; Kodera Y; Kim K; Goel A
    Clin Cancer Res; 2021 Apr; 27(8):2292-2300. PubMed ID: 33558424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer.
    Yang Y; Qu A; Zhao R; Hua M; Zhang X; Dong Z; Zheng G; Pan H; Wang H; Yang X; Zhang Y
    Mol Oncol; 2018 Dec; 12(12):2072-2084. PubMed ID: 30242969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 16-mRNA signature optimizes recurrence-free survival prediction of Stages II and III gastric cancer.
    Peng K; Chen E; Li W; Cheng X; Yu Y; Cui Y; Li Q; Wang Y; Xu X; Tang C; Gan L; Yu S; Liu T
    J Cell Physiol; 2020 Jul; 235(7-8):5777-5786. PubMed ID: 32048287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Transcriptomic Signature for Risk-Stratification and Recurrence Prediction in Intrahepatic Cholangiocarcinoma.
    Wada Y; Shimada M; Yamamura K; Toshima T; Banwait JK; Morine Y; Ikemoto T; Saito Y; Baba H; Mori M; Goel A
    Hepatology; 2021 Sep; 74(3):1371-1383. PubMed ID: 33725402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
    Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
    Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
    [No Abstract]   [Full Text] [Related]  

  • 7. A transcriptomic signature that predicts cancer recurrence after hepatectomy in patients with colorectal liver metastases.
    Wada Y; Shimada M; Morine Y; Ikemoto T; Saito Y; Baba H; Mori M; Goel A
    Eur J Cancer; 2022 Mar; 163():66-76. PubMed ID: 35042069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
    Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
    Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
    Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
    Front Immunol; 2022; 13():947802. PubMed ID: 36405735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomewide Expression Profiling Identifies a Novel miRNA-based Signature for the Detection of Peritoneal Metastasis in Patients With Gastric Cancer.
    Shimura T; Toden S; Kandimalla R; Toiyama Y; Okugawa Y; Kanda M; Baba H; Kodera Y; Kusunoki M; Goel A
    Ann Surg; 2021 Nov; 274(5):e425-e434. PubMed ID: 31663973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of a Robust Immune-Related Prognostic Signature for Gastric Cancer.
    Huo J; Wu L; Zang Y
    J Immunol Res; 2021; 2021():5554342. PubMed ID: 34007851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and validation of a prognostic nomogram based on a novel five-DNA methylation signature for survival in endometrial cancer patients.
    Li X; Yin F; Fan Y; Cheng Y; Dong Y; Zhou J; Wang Z; Li X; Wang J
    Cancer Med; 2021 Jan; 10(2):693-708. PubMed ID: 33350104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "3G" Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy.
    An O; Song Y; Ke X; So JB; Sundar R; Yang H; Rha SY; Lee MH; Tay ST; Ong X; Tan ALK; Ng MCH; Tantoso E; Chen L; Tan P; Yong WP;
    Cancer Res; 2021 May; 81(10):2788-2798. PubMed ID: 33558338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a Tumor Microenvironment-relevant Gene set-based Prognostic Signature and Related Therapy Targets in Gastric Cancer.
    Cai WY; Dong ZN; Fu XT; Lin LY; Wang L; Ye GD; Luo QC; Chen YC
    Theranostics; 2020; 10(19):8633-8647. PubMed ID: 32754268
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification of a 6-lncRNA prognostic signature based on microarray re-annotation in gastric cancer.
    Ma B; Li Y; Ren Y
    Cancer Med; 2020 Jan; 9(1):335-349. PubMed ID: 31743579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptomics-based liquid biopsy panel for early non-invasive identification of peritoneal recurrence and micrometastasis in locally advanced gastric cancer.
    Ding P; Wu H; Wu J; Li T; Gu R; Zhang L; Yang P; Guo H; Tian Y; He J; Yang J; Meng N; Li X; Meng L; Zhao Q
    J Exp Clin Cancer Res; 2024 Jun; 43(1):181. PubMed ID: 38937855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a molecular signature of prognostic subtypes in diffuse-type gastric cancer.
    Kim SK; Kim HJ; Park JL; Heo H; Kim SY; Lee SI; Song KS; Kim WH; Kim YS
    Gastric Cancer; 2020 May; 23(3):473-482. PubMed ID: 31773340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.
    Han C; Zhang C; Wang H; Li K; Zhao L
    BMC Cancer; 2021 Dec; 21(1):1312. PubMed ID: 34876056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A DNA methylation signature to improve survival prediction of gastric cancer.
    Peng Y; Wu Q; Wang L; Wang H; Yin F
    Clin Epigenetics; 2020 Jan; 12(1):15. PubMed ID: 31959204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A blood-based transcriptomic signature for noninvasive diagnosis of gastric cancer.
    Lee IS; Ahn J; Kim K; Okugawa Y; Toiyama Y; Hur H; Goel A
    Br J Cancer; 2021 Sep; 125(6):846-853. PubMed ID: 34163003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.